AbCellera Biologics Inc. (ABCL): Results of Operations and Financial Condition
AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE AbCellera Reports Q2 2026 Business Results 8/5/2026 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars,
How this was made
The 30-second read
Why it matters
Traders can update models for cash runway, burn rate, and the probability-weighted value of upcoming clinical catalysts, especially the ABCL635 Phase 2 top-line readout expected in August 2026.
Market read
Primary disclosure of Q2 financials, liquidity, and near-term clinical timing plus new pharma collaboration upfront cash.
What to watch
Partner program count declined (35 downstream programs vs 44 at Dec 31, 2025), which could signal shifting prioritization even as new collaborations add upfront funding.
AbCellera Reports Q2 2026 Business Results
Revenue declined to $4.1 million and net loss widened to $55.4 million, while SG&A expense declined, liquidity remained above $675 million, and the company advanced clinical and collaboration milestones.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, Q2 2026other | $4.1 million | – | – |
| Research fees, Q2 2026other | $3,901 thousand | – | – |
| Licensing and royalty revenue, Q2 2026other | $149 thousand | – | – |
| Research and development expenses, Q2 2026other | $46.0 million | – | – |
| Sales, general, and administrative expenses, Q2 2026other | $13.9 million | – | – |
| Depreciation and amortization, Q2 2026other | $6,990 thousand | – | – |
| Total operating expenses, Q2 2026other | $66,827 thousand | – | – |
| Loss from operations, Q2 2026other | $(62,777) thousand | – | – |
| Interest and other, Q2 2026other | $42 thousand | – | – |
| Grants and incentives, Q2 2026other | $(3,854) thousand | – | – |
| Total other income, Q2 2026other | $(3,812) thousand | – | – |
| Loss before income tax, Q2 2026other | $(58,965) thousand | – | – |
| Income tax recovery, Q2 2026other | $(3,538) thousand | – | – |
| Net loss, Q2 2026other | $55.4 million | – | – |
| Comprehensive loss, Q2 2026other | $(56,160) thousand | – | – |
| Net loss per share, basic, Q2 2026other | $(0.18) per share | – | – |
| Net loss per share, diluted, Q2 2026other | $(0.18) per share | – | – |
| Weighted-average common shares outstanding, basic, Q2 2026other | 305,557,294 | – | – |
| Weighted-average common shares outstanding, diluted, Q2 2026other | 305,557,294 | – | – |
| Total revenue, six months ended June 30, 2026other | $12,362 thousand | – | – |
| Research and development expenses, six months ended June 30, 2026other | $92,649 thousand | – | – |
| Sales, general, and administrative expenses, six months ended June 30, 2026other | $26,185 thousand | – | – |
| Total operating expenses, six months ended June 30, 2026other | $132,662 thousand | – | – |
| Net loss, six months ended June 30, 2026other | $(98,592) thousand | – | – |
| Net loss per share, basic, six months ended June 30, 2026other | $(0.32) per share | – | – |
| Net loss per share, diluted, six months ended June 30, 2026other | $(0.32) per share | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Research feesReported revenue component. | $3,901 thousand | – | – |
| Licensing and royalty revenueReported revenue component. | $149 thousand | – | – |
August 2026 and Q4 2026 outlook
- NoteABCL635 top-line data readout from the Phase 2 trial expected in August 2026.
- NoteABCL575 top-line data readout expected in Q4 2026.
- NoteThe third Jazz research program will initiate within 12 months.
What drove it
- AbCellera completed enrollment for the Phase 2 study of ABCL635.
- ABCL386 and ABCL688 are progressing through IND-enabling activities.
- The company completed dosing for the Phase 1 study of ABCL575.
- The Jazz Pharmaceuticals plc collaboration covers next-generation T-cell engagers for multiple gastrointestinal cancers and other solid tumors.
- Jazz upfront payments total $84 million, consisting of $56 million for the first two research programs and $28 million for a third program.
- The subsequent Vertex Pharmaceuticals Incorporated collaboration covers multispecific T-cell engagers for autoimmune diseases and other conditions and includes $28 million in total upfront payments.
- Partners led 35 programs progressing at the end of Q2 2026 where AbCellera holds a downstream stake.
- AbCellera held downstream stakes in 12 molecules in the clinic understood to be progressing on June 30, 2026.
Concerns
- Total revenue was $4.1 million, compared to $17.1 million in Q2 2025.
- Net loss was $55.4 million, compared to a net loss of $34.7 million in Q2 2025.
- R&D expenses were $46.0 million, compared to $39.2 million in Q2 2025.
- Partners led 35 progressing programs at the end of Q2 2026, down from 44 on December 31, 2025.
- ABCL635 and ABCL575 readout timing is forward-looking.
What to watch
- ABCL635 Phase 2 top-line data expected in August 2026.
- ABCL575 Phase 1 top-line data expected in Q4 2026.
- Initiation of the third Jazz research program within 12 months.
- Receipt and recognition of collaboration economics, including Jazz's $84 million in total upfront payments and Vertex's $28 million in total upfront payments.
- Progression of the 35 partner-led programs and 12 clinical molecules in which AbCellera holds downstream stakes.
Balance sheet and cash flow
- Cash and cash equivalents were $120,065 thousand at June 30, 2026.
- Marketable securities were $420,039 thousand at June 30, 2026.
- Total cash, cash equivalents, and marketable securities were $540,104 thousand at June 30, 2026.
- The company reported over $565 million in total cash balances and marketable securities.
- Available non-dilutive government funding was $110 million, bringing total available liquidity to over $675 million.
- Operating lease liability was $129,948 thousand at June 30, 2026.
- Net cash used in operating activities for the six months ended June 30, 2026 was $(7,600) thousand.
- Purchases of property and equipment for the six months ended June 30, 2026 were $(5,963) thousand.
- Net cash used in investing activities for the six months ended June 30, 2026 was $(13,740) thousand.
- Net cash provided by financing activities for the six months ended June 30, 2026 was $13,585 thousand.
- Decrease in cash and cash equivalents for the six months ended June 30, 2026 was $(8,223) thousand.
Analysis
AbCellera reported a lower-revenue and higher-loss second quarter. Total revenue was $4.1 million versus $17.1 million in Q2 2025. The decline included research fees of $3,901 thousand versus $6,639 thousand and licensing and royalty revenue of $149 thousand versus $10,445 thousand. Net loss was $55.4 million, or $(0.18) per share on both a basic and diluted basis, compared with net loss of $34.7 million, or $(0.12) per share, in Q2 2025.
Expense trends were mixed. R&D expenses increased to $46.0 million from $39.2 million, while SG&A expenses declined to $13.9 million from $22.0 million. Total operating expenses were $66,827 thousand compared with $66,669 thousand, and loss from operations was $(62,777) thousand compared with $(49,585) thousand. For the six months ended June 30, 2026, total revenue was $12,362 thousand and net loss was $(98,592) thousand.
The balance sheet and liquidity position remain central to the reported strategy. AbCellera ended June 30, 2026 with $120,065 thousand of cash and cash equivalents and $420,039 thousand of marketable securities, for $540,104 thousand in total cash, cash equivalents, and marketable securities. The company separately stated that it had over $565 million in total cash balances and marketable securities, plus $110 million in available non-dilutive government funding, for over $675 million in total available liquidity. Net cash used in operating activities was $(7,600) thousand for the six months ended June 30, 2026.
The operating update emphasizes near-term clinical and collaboration events. ABCL635 Phase 2 top-line data are expected in August 2026, and ABCL575 Phase 1 top-line data are expected in Q4 2026. The Jazz collaboration carries $84 million in total upfront payments, and the subsequent Vertex collaboration carries $28 million in total upfront payments. At the same time, the number of partner-led programs progressing in which AbCellera holds a downstream stake was 35 at the end of Q2 2026, down from 44 on December 31, 2025.
Management, verbatim
Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon,
Carl Hansen, Ph.D., founder and CEO of AbCellera
Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic and are adding over $100 million in upfront cash to our balance sheet.
Carl Hansen, Ph.D., founder and CEO of AbCellera
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income
- GAAP designation for reported financial metrics
- Non-GAAP financial metrics and reconciliations
- Quarter-over-quarter comparisons
- Percentage revenue, expense, earnings, or margin changes
- Financial revenue, expense, gross margin, operating expense, or tax-rate guidance
- Prior-period outlook for comparison
- Free cash flow
- Share repurchases
- Dividend declarations or payments
- Debt balance separately identified as debt
- Quarterly operating cash flow
- Quarterly capital expenditures
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The document is AbCellera’s SEC Form 8-K (Item 2.02) attaching its Q2 2026 business results press release and program updates.
Ticker impact
AbCellera reported Q2 2026 results, including a $55.4M net loss, $565M+ cash, and reiterated ABCL635 Phase 2 top-line timing for August 2026.
Near-term volatility likely around expectations for the August 2026 ABCL635 top-line readout, with sentiment supported by large upfront collaboration cash but tempered by weaker Q2 revenue.
This is a primary SEC 8-K with concrete financial datapoints, liquidity figures, and specific program milestones and collaboration upfront payments.
Market effects
Reinforces ongoing capital inflows to clinical-stage biotech via T-cell engager collaborations, but highlights persistent revenue volatility typical of platform companies.
Limited direct regional spillover; primarily affects US-listed biotech sentiment.
Collaboration announcements with major pharma (Jazz, Vertex) can marginally influence broader immuno-oncology deal expectations.
Counterpoint
The upfront cash and liquidity may not offset dilution risk if clinical timelines slip or if revenue remains minimal until later-stage commercialization.
Key entities
- issuerAbCellera Biologics Inc.
Clinical-stage biotech reporting Q2 2026 financial results, liquidity, and collaboration/program updates.
- clinical_programABCL635
Phase 2 study with top-line data readout expected in August 2026.
- collaboration_partnerJazz Pharmaceuticals plc
Announced collaboration for next-generation T-cell engagers; includes $84M total upfront payments across programs.
- collaboration_partnerVertex Pharmaceuticals Incorporated
Announced collaboration for multispecific T-cell engagers for autoimmune diseases; includes $28M total upfront payments.
